Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis

doi:10.3969/j.issn.1006-7795.2025.02.006

Journal of Capital Medical University ›› 2025, Vol. 46 ›› Issue (2): 210-215.doi: 10.3969/j.issn.1006-7795.2025.02.006

Previous Articles Next Articles

Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis

Shi Feng¹, ZhaoYanjie², Gao Ying¹, Song Qingkun^3*

1.Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;2.Department of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;3.Department of Biomedical Information Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

Received:2024-11-18 Online:2025-04-21 Published:2025-04-14
Supported by:
This study was supported by Beijing Municipal Administration of Hospitals Incubating Program（PX2021031）.

Abstract

Abstract: Objective To investigate the prognostic effect of CD38 in patients with esophageal squamous cell carcinoma patients (ESCC). Methods A retrospective cohort study with 142 ESCC patients was performed. The clinicopathological features and expression of CD38, CD4, CD8, Ki-67, programmed cell death ligand 1(PD-L1) and programmed cell death 1(PD-1) in tumor and immune cells were evaluated. Results Among ESCC patients with lymph node metastasis, the expression of CD38 had a significant association with the overall survival (P=0.037). The median overall survival was 14 months and 38 months among patients with low and high expression of CD38, respectively. The crude and adjusted hazard ratio of high CD38 expression was 0.46 (95%CI： 0.21-0.98) and 0.32 (95%CI： 0.13-0.76) respectively. The expression of CD38 had a negative correlation with PD-L1 expressed in tumor cells. Conclusion The high expression of CD38 was associated with a better survival for ESCC with lymph node metastasis.

Key words: esophageal squamous cell carcinoma, CD38, tumor-infiltrating immune cells, immune microenvironment, programmed cell death ligand 1

CLC Number:

R735

Shi Feng, ZhaoYanjie, Gao Ying, Song Qingkun. Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis[J]. Journal of Capital Medical University, 2025, 46(2): 210-215.

References

［1］刘润泽, 常栋, 李博闻. 食管鳞癌免疫治疗的临床进展［J］. 中华肿瘤防治杂志, 2021, 28 (13): 1028－1032.
［2］刘淑君, 苗浩, 王颖, 等. PD-1抑制剂联合化疗治疗晚期食管鳞状细胞癌的疗效评估及预后分析［J］. 中华肿瘤防治杂志, 2023, 30 (7): 406-411，429.
［3］Konen J M, Fradette J J, Gibbons D L. The good, the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors［J］. Cells, 2019, 9(1): 52.
［4］Morandi F B, Airoldi I, Marimpietri D, et al. CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies［J］. Cells, 2019, 8(12): 1527.
［5］Wo Y J, Gan A S P, Lim X, et al. The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy［J］. Cells, 2019, 9(1): 26.
［6］贺正希, 刘惺, 周艳宏. CD38在临床肿瘤治疗中作用的研究进展［J］. 中南大学学报:医学版, 2022, 47(7): 952－959.
［7］Chen L M, Diao L X, Yang Y B, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade［J］. Cancer Discov, 2018, 8(9): 1156－1175.
［8］Zhang M, Yang J, Zhou J, et al. Prognostic values of CD38⁺CD101⁺PD1⁺CD8⁺ T cells in pancreatic cancer［J］. Immunol Invest, 2019, 48(5): 466－479.
［9］Debashree B, Soumya M, Swadeep K S, et al. Intratumoral PD1⁺CD38⁺Tim3⁺CD8⁺T cells in pre-BCG tumor tissues are associated with poor responsiveness to BCG immunotherapy in patients with non-muscle invasive bladder cancer［J］. Cells, 2023: 1939.
［10］Liu X, Grogan T R, Hieronymus H, et al. Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome［J］. Cell Rep, 2016, 17(10): 2596－2606.
［11］Lam J H, Ng H H M, Lim C J, et al. Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma［J］. Front Immunol, 2019, 10: 2093.
［12］Yeong J, Lim J C T, Lee B, et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer［J］. Front Immunol, 2018, 9: 1209.
［13］Sahoo D, Wei W, Auman H, et al. Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer［J］. Oncotarget, 2018, 9(5): 6550－6561.
［14］Li Y, Lu Z L, Che Y, et al. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma［J］. Oncoimmunology, 2017, 6(11): e1356147.
［15］Dwivedi S, Rendón-Huerta E P, Ortiz-Navarrete V, et al. CD38 and regulation of the immune response cells in cancer［J］. J Oncol, 2021, 2021: 6630295.
［16］Marie J Y R, Masayuki O, Justine J W S, et al. CD38 marks the exhausted CD8+tissue-resident memory T cells in hepatocellular carcinoma［J］. Front Immunol, 2023, 14: 1182016.
［17］Heimes A S, Riedel N, Almstedt K, et al. Prognostic impact of CD38-and IgκC-positive tumor-infiltrating plasma cells in triple-negative breast cancer［J］. Int J Mol Sci, 2023, 24(20): 15219.
［18］Mimura K Y L, Ujiie D, Hayase S, et al. Immunotherapy for esophageal squamous cell carcinoma:a review［J］. Fukushima J Med Sci, 2018, 64(2): 46－53.
［19］Liu D, Xu H P, Shih C, et al. T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction［J］. Nature, 2015, 517(7533): 214－218.
［20］孙小虎, 王璐, 白静慧, 等. 晚期肝癌免疫微环境CD38表达水平与PD-1抑制剂疗效相关性分析［J］. 肝脏, 2023, 28(1): 75－78, 94.
［21］Chatterjee S, Daenthanasanmak A, Chakraborty P, et al. CD38-NAD⁺axis regulates immunotherapeutic anti-tumor T cell response［J］. Cell Metab, 2018, 27(1): 85－100.e8.

Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics

Comments